Is Pfizer Stock Underperforming the Dow?

New York-based Pfizer Inc. (PFE) is one of the world's largest pharmaceutical companies valued at $164.4 billion by market cap. The company is involved in the discovery, development, manufacturing, marketing, and distribution of biopharmaceutical products. Pfizer offers a broad range of medicines and vaccines across therapeutic areas such as oncology, inflammation and immunology, rare diseases, hospital care, and internal medicine.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and PFE fits right into that category. Pfizer excels with its diverse product portfolio, including leading drugs like Prevnar 13, Ibrance, and Eliquis, supported by a strong R&D focus and the strategic acquisition of Seagen to enhance its oncology offerings. The company's substantial global market presence, with nearly 50% of sales coming from international markets, highlights its capability to navigate diverse markets and meet global healthcare demands.